FDA Wakes Up to Insomnia Drug Risk

The Food and Drug Administration has recommended that the bedtime dose of the insomnia drug zolpidem be lowered because there's new evidence that, after taking the current dose, the level of drug remaining in patients' blood the next morning can impair activities that require mental alertness, including driving.

The FDA has received adverse event reports of driving impairment and car accidents associated with zolpidem, but it wasn't until clinical data using driving simulation and laboratory studies were conducted that the agency understood the full extent of the problem.

Zolpidem is available as a generic and is also a component of Sanofi's Ambien and Ambien CR, Meda Pharmaceuticals' Edluar, and NovaDel Pharma's (NASDAQOTH: NVDL) Zolpimist. Intermezzo, developed by Purdue Pharma and Transcept Pharmaceuticals , also contains zolpidem, but it's already dosed at a lower level since it's used for middle-of-the-night insomnia.


The drug is eliminated slower in women than in men, so the FDA is requiring drugmakers to lower the recommended dose for women from 10 mg to 5 mg for immediate-release products and from 12.5 mg to 6.25 mg for extended-release products. The new labels will also note that doctors should consider prescribing the lower doses to men as well.

link

The article FDA Wakes Up to Insomnia Drug Risk originally appeared on Fool.com.

Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Income Investing

Grow your nest-egg.

View Course »

Add a Comment

*0 / 3000 Character Maximum